Tenofovir Use Over Five Years Linked to Lower Liver Cancer Risk

Tenofovir is a potent antiviral medication primarily used to treat chronic hepatitis B infection. Long-term use of this drug, particularly over a five-year period, has been associated with a reduced risk of developing liver cancer.

Studies have shown that patients who take tenofovir for at least five years experience a liver cancer incidence rate of approximately 3% to 4%. In contrast, individuals with chronic hepatitis B who do not receive antiviral treatment face a significantly higher risk, with liver cancer rates exceeding 10% in some cases.

Suppressing the hepatitis B virus plays a critical role in reducing liver cancer risk. Since chronic hepatitis B is a major risk factor for liver cancer, effective antiviral therapy like tenofovir can significantly decrease the likelihood of malignant liver changes.

However, treatment decisions should always be based on individual health conditions. Patients with normal liver function tests, undetectable hepatitis B viral load, and no signs of liver fibrosis or cirrhosis on imaging may not require immediate antiviral intervention.

Early antiviral treatment is recommended when abnormalities are detected. If a patient shows signs of liver damage, elevated viral load, or other complications, starting tenofovir therapy early can provide significant long-term benefits, including a lower risk of liver cancer and improved overall liver health.

It is always best for patients to consult with a hepatologist or infectious disease specialist to determine the most appropriate treatment plan based on their specific condition and medical history.